AzTrials
AzTrials

Chronic PainEarly Phase 1NCT00677911

Immunologic Response to Negative Cognition in Persons With Chronic Pain

A Early Phase 1 study testing In-vivo pain catastrophizing induction in people with Chronic Pain, run by Oregon Health and Science University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Principal Investigator/Program Director (Last, First, Middle): Darnall, Beth APS Future Leaders in Pain Small Research Grants Application Page 5 Continuation Format Page Summary: Chronic pain is stressful, both physically and psychologically. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Chronic Pain
What is being tested?
In-vivo pain catastrophizing induction
How many people
47 participants
Where
1 siteUnited States
Study dates
Feb 2007to Dec 2007
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • ages 18-65
  • chronic musculoskeletal pain
  • being treated for chronic pain at OHSU

Who cannot join

  • suicidality or thought disorder
  • pregnant
  • poor venous access
  • current corticosterioid regimen
  • recent or active virus or infection
  • substance abuse
  • former IV drug user

Trial locations and contacts

1 site in 1 country.

United States1 site
  • OCTRI; OHSU Mail Code: CHH 13th floor 3303 Bond St.

    Portland, Oregon, 97239

Other trials in United States

About this study

Principal Investigator/Program Director (Last, First, Middle): Darnall, Beth APS Future Leaders in Pain Small Research Grants Application Page 5 Continuation Format Page

Summary: Chronic pain is stressful, both physically and psychologically. Stressful experiences induce autonomic nervous system arousal, which reliably leads to inflammation and immune suppression. Inflammation then exacerbates existing pain and may be a key factor in both the genesis and maintenance of pain. Stress-induced immune effects are detected two hours (2 hrs) post-stressor, suggesting only a few stressful experiences per day may be sufficient to sustain elevated pain levels1. Cognition has emerged as a potential mediating factor in the relationship between pain and stress. Mentally recreating an emotionally stressful event induces de novo physiological stress1. In other words, thinking about an emotionally charged event down-regulates autonomic stress responses and subsequent immune effects. Therefore, exploring cognition as a mediating factor between stress, pain, and inflammation will inform our understanding of pain pathways, as well as improve treatment for pain.

Read more

Study Rationale: The acute stress response induces immunosuppression; however, this relationship has been studied in arbitrary models only (shock avoidance, job interview). This study employs the novel approach of examining stress and immune responses to a personally relevant stressor (pain); prior studies used arbitrary models only (shock avoidance, job interview). Pain offers a highly salient and personal context well-suited for investigation of negative cognitive perseveration. Pain is acutely sensitive to exacerbation via inflammation, and thus the relevance of examining immune effects of rumination on future negative expectations ("expecting the worst") is underscored.

Goal: To test the biological consequences of negative expectations, achieved via an active 10-minute negative cognitive perseveration on a personally relevant stressor: future worsening of one's chronic pain condition. Biological stress response will be measured via heart rate (HR), blood pressure (BP) and serum cortisol. Impact of negative cognition on inflammation will be measured using interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) as biomarkers of immune function, controlling for depression and pain catastrophizing. This study aims to inform the understanding of pain mechanisms.

Aim 1: Determine the magnitude of an autonomic stress response to an induction of negative cognition.

Aim 2: Determine immune effects of the experiment-induced stress response.

Aim 3: Establish whether a pre-existing tendency to catastrophize mediates the relationship between experiment-induced negative perseveration and immune effects.

Aim 4: Establish whether stress-related increases in IL-6 remain elevated post 2 hrs.

Read the detailed description

Methods: This prospective study examines the magnitude of biological stress and subsequent immunologic changes in response to negative cognitive perseveration. Five physiological measurement time points occur over the course of the 3 hour experiment.

Demographics and health characteristics of interest: gender, marital status, smoking status, education level, race, height, weight, body mass index, medical comorbidity, psychological comorbidity, medications (for inflammation, pain, or psychiatric conditions).

Inclusionary Criteria

  • >18 years of age; <65 years of age
  • Non-inflammatory musculoskeletal patients presenting for evaluation at Oregon Health \& Science University (OHSU) Comprehensive Pain Center (CPC)

Exclusionary Criteria

  • Active or recent virus/infection
  • Thought disorder, Suicidality,
  • Substance Abuse
  • Active corticosteroid regimen
  • Pregnancy
  • Limited venous access
  • Former intravenous drug user

Enrollment: All persons presenting for evaluation at the CPC who meet study criteria will be offered the option to participate in the study. Approximately 60 new pain patients are evaluated by psychology monthly and we expect to obtain our goal of 40 participants within 6 months. Informed consent will be obtained in compliance with OHSU Institutional Review Board protocol. Subjects will receive $100 gift certificate compensation, even if they fail to complete the study. We anticipate a low completion failure rate as the study is completed in one 3-hour time block. Study times will be standardized to account for circadian effects. Participants will be told to arrive having eaten a light breakfast with minimal caffeine consumption (e.g., less than 2 cups of coffee). They will be given a subject number and their psychiatric diagnoses will be blinded to prevent bias. The study involves gathering 5 serum samples and thus participants will be catheterized by nursing staff to minimize physiological stress.

Principal Investigator/Program Director (Last, First, Middle): Darnall, Beth APS Future Leaders in Pain Small Research Grants Application Page 7 Continuation Format Page

Study site: The study will be conducted at the NIH-funded General Clinical Research Center (GCRC). The GCRC provides state of the art resources including research space, specialized research nurses to perform blood draws and gather biodata, biostatisticians, and sophisticated laboratories to perform serum biomarker analysis. OHSU's GCRC is Oregon's premier multidisciplinary patient-oriented research facility and is housed in the same building as the CPC, thus minimizing travel burden on participants.

Active Stress Induction: Negative Cognitive Perseveration On their experiment day, participants will interface with a licensed clinical psychologist who did not perform their clinical interview and who is blinded to their diagnoses. The psychologist will instruct the participant talk for 10 minutes about the worst aspects of their pain, to discuss their loss of control over their situation, the negative impact pain has had on their life and others. They will be guided to imagine that their situation will progressively worsen, and to focus on how badly they will feel as a result. Two measures of induction efficacy will be given: subjective verbal rating (0-10) and objective rating by attending psychologist (0-10). The intervention ends at 10 minutes and the remainder of the study involves biodata measurement.

Study ends at 2.5 hrs post induction following the final blood draw. The psychologist will debrief subjects and will assess their affective state. Their subjective units of distress will be checked. Persons who are in a continued negative cognitive state will receive 30 minutes of Cognitive Behavioral Therapy (CBT) by the on-site psychologist. Care will be taken not to allow participants to leave the study site in distress. Participants will receive follow up psychology care at the CPC as indicated in their treatment plan.

Conditions
Chronic Pain
Being tested
In-vivo pain catastrophizing induction
Keywords
Chronic pain, Interleukin-6, pain catastrophizing, cytokines, cortisol
Medical subject headings
Chronic Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • In-vivo pain catastrophizing inductionBehavioural

    All participants underwent a 10-minute in-vivo pain castastrophizing induction.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Interleukin-6

    Measured: cross-sectional

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 May 2008 (estimated)
  2. Study startFeb 2007
  3. Primary completionDec 2007
  4. Study completionDec 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Other
Allocation
Non-randomised
Intervention model
Single group
Enrolment
47 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00677911
Sponsor's protocol ID
OCTRI975
Status last verified
Jul 2019
First submitted
13 May 2008
Last updated
26 Jul 2019
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing In-vivo pain catastrophizing induction in people with Chronic Pain, run by Oregon Health and Science University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Interleukin-6 (time frame: cross-sectional). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jul 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in